Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
-
Narrated by:
-
By:
About this listen
In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients.
Subscribe to Eagle’s Eye View
activate_mytile_page_redirect_t1
What listeners say about Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.